Therapeutic effect of transcatheter arterial chemoembolization combined with tyrosine kinase inhibitor and Camrelizumab on advanced hepatocellular carcinoma
Objective:To investigate the therapeutic effect of transcatheter arterial chemoembolization(TACE)combined with tyrosine kinase inhibitor(TKI)and Camrelizumab in the treatment of advanced hepatocellular carcinoma(HCC).Methods:Sixty patients with advanced HCC admitted to Xinzheng Huaxin People's Hospital from January 2021 to January 2022 were selected and randomly divided into two groups,with 30 cases in each group.Both groups were treated with TACE combined with TKI,and the observation group was treated with Camrelizumab.Both groups of patients were treated for three months.Short-term and long-term treatment effects,serum tumor marker levels and adverse events during treatment were compared between the two groups.Results:Before treatment,there was no statistically significant difference in maximum diameter of tumors between the two groups(P＞0.05).After treatment,maximum diameter of tumors in both groups were shorter than that before treatment,and the observation group was shorter than the control group(P＜0.05).After treatment,disease control rate in the observation group was higher than that in the control group,and progressive disease rate in the observation group was lower than that in the control group(P＜0.05).There were no statistically significant differences in objective response rate,complete remission rate,partial response rate and stable disease rate between the two groups(P＞0.05).Progression free survival(PFS)of the control group was 56.67% after three months of follow-up,40.00% after six months of follow-up,and 36.67% after 12 months of follow-up;PFS of the observation group was 93.33% after three months of follow-up,70.00% after six months of follow-up,and 63.33% after 12 months of follow-up.Before treatment,there was no statistically significant difference in levels of alpha fetoprotein(AFP)between the two groups(P＞0.05).After treatment,AFP levels in both groups were lower than that before treatment,and the observation group was lower than the control group(P＜0.05).There were no statistically significant differences in incidence rate of liver function injury,severe liver function injury,hypertension,hand foot syndrome,fever,pain and lymphocyte reduction between the two groups during treatment(P＞0.05).Conclusions:In the treatment of advanced HCC,the triple therapy of TACE,TKI and Camrelizumab is more effective than TACE combined with TKI,and the incidence of adverse events is equivalent to that of TACE combined with TKI treatment.
万方数据
维普
